The study explores the action of amlodipine, a drug used commonly to treat hypertension, on lung cancer cells. Lung cancer is one of the leading causes of cancer-related deaths globally, and the currently available treatment strategies like chemotherapy are associated with critical side effects and diminish efficacy over time due to the emergence of chemoresistance.
The objective of this research is to examine how amlodipine impacts lung cancer cells, NSCLC cells. Scientists have carried out numerous experiments to determine the viability, migration, and invasion of cells treated with a fluctuating concentration of amlodipine. According to their results, they found that amlodipine significantly inhibited cancer cell growth in a dose-dependent manner. It shows that as the concentration of amlodipine increased, the growth of cancer cells reduced.
In addition, amlodipine was found to reduce the invasive and migratory capacity of cancer cells into adjacent tissues, processes crucial to cancer development and metastasis. The research also did metabolomic analysis using advanced methods like ultra-high-performance liquid chromatography-electrospray ionization quadrupole time-of-flight mass spectrometry (UHPLC-ESI-QTOF-MS) to find out changes in the metabolic profile of cells treated with amlodipine.
The metabolomic profiling revealed that some metabolites were highly dysregulated in amlodipine-treated cells. Some metabolites such as citramalic acid, L-proline, dGMP, L-glutamic acid, niacinamide, and L-acetylcarnitine were significantly altered. These metabolites play key roles in various cellular processes such as the production of energy, DNA synthesis, and signaling processes. The researchers found that amlodipine possesses anticancer activity through inhibiting the growth, migration, and invasion of lung cancer cells. The metabolomic changes offer hints at the mechanisms of amlodipine’s anticancer activity, indicating that it can affect crucial metabolic pathways for the survival and growth of cancer cells.
Overall, this research points to the therapeutic application of repurposed amlodipine in the treatment of lung cancer as a promising direction toward overcoming chemoresistance and the enhancement of cancer therapeutic outcomes. Additional experiments are required in order to completely clarify molecular mechanisms and further validate these data in clinical conditions.
